Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Aviva in collaboration to attack liver toxicity problems
June 2007
SHARING OPTIONS:

SAN DIEGOŚAviva Systems Biology has entered into a collaborative agreement with the Seattle-based non-profit Institute for Systems Biology (ISB) to develop new antibodies for liver toxicity biomarker discovery. Under the agreement, the ISB is providing Aviva Systems Biology with a list of proteins for which Aviva will produce antibodies. ISB will then assess the antibodies for efficacy and, if appropriate, use them to identify possible biomarker proteins that indicate early liver toxicity. Aviva currently has an inventory over 12,000 target peptide specific antibodies that represent more than 4,000 novel human and mouse targets.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.